President and Chief Executive Officer of AskGene Pharma since its inception , which  is located at Thousand oaks, Los Angeles.

More than 25 years’ experience in clinical pharmacology, including more than 12 years in PK/PD and drug development across various therapeutic areas ,>10 years at Amgen  and Genetech with  Increasing responsibility up as Scientific Director  in charge of molecule dose-selection for all oncology programs

Ph.D. in Pharmaceutics from China Pharmaceutical University and completed his post-doctoral training at the University of California San Francisco (UCSF). 

Dr. Lu’s previous posts included Pharmacometrician  at Genentech and progressed to a Scientific Director at Amgen. During his tenure, he participated in the first BLA filing of Avastin and the first NDA filing of Tarceva. Additionally, Dr. Lu was responsible for PK/PD assessment, dose selection, and study design for many projects from pre-clinical stage to phase I, II and III, and regulatory BLA/NDA and IND filings of marketed products including Avastin, Tarceva, Herceptin, Lucentis, and T-DM1, etc.

美国AskGene公司总裁&首席执行官； 
卢建丰博士在临床药理学方面有超过25年的行业经验，从事多个治疗领域的PK/PD和药物开发工作12年以上；在美国基因泰克和安进公司担任科学总监且有10年以上的的定量药理经验，期间负责所有抗肿瘤项目的分子剂量选择工作。 
中国药科大学博士、美国加州大学旧金山分校博士后；
过往工作经历包括基因泰克的定量药理科学家，并晋升为安进的科学总监，在任期间，参与过安维汀的首次BLA和特罗凯首次NDA相关设计和准备工作。此外，卢建丰博士负责从临床前阶段到临床I期、II期、III期多个项目的PK/PD评估、剂量选择和研究设计工作，以及上市产品的BLA/NDA注册和IND申报工作，其中包括安维汀、赫赛汀、特罗凯、雷株单抗和T-DM1等项目。